
|Slideshows|June 26, 2018
ADA 2018: New Basal Insulins go Head-to-Head
Author(s)Kenneth J. Bender, PharmD, MA
How do 2nd generation basal insulin formulations perform vs their predecessors? We report highlights of 3 important studies from the ADA 78th Scientific Sessions.
Advertisement
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis: Daily Dose
2
Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease
3
Dupilumab Meets All Endpoints in Phase 3 Study for Allergic Fungal Rhinosinusitis; FDA Grants Priority Review
4
CagriSema Reduces SBP by 10.9 mmHg in Post Hoc Analysis of REDEFINE 1 Trial
5






























































































































































































































































































